Effect of Testosterone Propionate on Erythropoiesis after Experimental Orchiectomy

Open access


INTRODUCTION: Androgen deficiency anemia occurs most frequently in pharmacogenic suppression of androgen synthesis or with advancing age in men. Bilateral orchiectomy is a surgical modality used in the treatment of metastatic prostate carcinoma. It is accompanied by marked decrease in circulating serum levels of androgens. AIM: The aim of the experimental study was to determine the effect of substitution therapy with testosterone propionate (TP) on some haematological parameters of erythropoiesis in male rats after orchiectomy.

MATERIAL AND METHODS: Eighty Wistar male rats with mean weight of 252.3 g were used in the study. The animals were allocated into 2 control orchidectomized groups, 2 shamoperated groups and 4 experimental orchidectomized groups. Testosterone propionate was administered intramuscularly, once a week at a dose of 4 mg and 8 mg per kilogram of body weight for 15 days and for 15 weeks. Erythrocyte count was performed and hemoglobin and hematocrit levels were measured.

RESULTS: In the chronic experiment there was a significant decrease in red blood cells and hemoglobin, and a tendency of decrease in hematocrit after orchiectomy. The effect of TP on erythropoiesis in orchiectomised rats is dose-dependent.

CONCLUSION: TP replacement therapy in doses of 4 mg/kg and 8 mg/kg has a stimulating effect on erythropoiesis only in chronic administration.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Werner A. The Male Climacteric. JAMA 1939; 112(15):1441-3.

  • 2. Kumanov Ph. The Male Climacteric? Sofi a: AB Studio 2002 (Bulgarian).

  • 3. Chen H Zirkin BR. Long-term suppression of Leydig cell steroidogenesis prevents Leydig cell aging. Proc Natl Acad Sci USA 1999;96(26):14877-81.

  • 4. Luo L Chen H Zirkin BR. Temporal relationships among testosterone production steroidogenic acute regulatory protein (StAR) and P450 side-chain cleavage enzyme (P450scc) during Leydig cell aging. J Androl 2005;26(1):25-31.

  • 5. Shahani S Braga-Basaria M Maggio M Basaria S et al. Androgens and erythropoiesis: past and present. J Endocrinol Invest 2009;32(8):704-16.

  • 6. Li ZB Wang J Wang JX et al. Testosterone therapy improves cardiac function of male rats with right heart failure. Zhonghua Nan Ke Xue 2009;15(11):994-1000 (Chinese).

  • 7. Locasciulli A Porta F Vossen JM Bacigalupo A. Treatment of acquired severe aplastic anaemia (SAA) in children: an analysis of the EBMT-SAA working party (abstract). Bone Marrow Transplant 1989;(Suppl 2) 4:90.

  • 8. Dainiak N. The role of androgens in the treatment of anemia of chronic renal failure. Semin Nephrol 1985;5:147.

  • 9. Labunets IF Butenko GM Dragunova VA et al. The pineal gland’s peptides factors and the rhythms of functions of the thymus and bone marrow in animals during aging. Adv Gerontol 2004;13:81-9 (Russian).

  • 10. Bassil S Alkaade S Morley J. The benefi ts and risks of testosterone replacement therapy: a review Nazem Ther Clin Risk Manag 2009;5:427-48.

  • 11. Swerdloff R Wang C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 2003;6(3):207-11.

  • 12. Nemeth N Kiss F Magyar Z et al. Following-up hemorheological consequences of gonadectomy in male and female rats. Clin Hemorheol Microcirc 2012;50(4):231-43.

  • 13. Nemeth N Kiss F Hever T Brath E et al. Hemorheological consequences of hind limb ischemiareperfusion differs in normal and gonadectomized male and female rats. Clin Hemorheol Microcirc 2012;50(3):197-211.

  • 14. Zirkin B. Animal models of aging males. The Aging Male 1998;Supp1:1-15.

  • 15. Mirand E Gordon A. Mechanism of estrogen action in erythropoiesis. Endocrinol 1965;78:325-32.

  • 16. Faustini-Fustini M Rochira V Carani C. Oestrogen defi ciency in men: where are we today? Eur J Endocrinol 1999;140:111-29.

  • 17. T’Sjoen GG Beguin Y Feyen E et al. Infl uence of exogenous oestrogen or (anti-) androgen administration on soluble transferrin receptor in human plasma. J Endocrinol 2005;186:61-7.

  • 18. Dickerman RD Pertusi R Miller J et al. Androgeninduced erythrocytosis: is it erythropoietin? Am J Hematol 1999;61:154-5.

  • 19. Raich PC Korst DR. Plasma erythropoietin levels in patients undergoing long-term hemodialysis. Arch Pathol Lab Med 1978;102:73-5.

  • 20. Ali BH Ahmed IH. Hormonal replacement therapy in an animal model with chronic renal failure and gonadectomy: biochemical and hematological study. Ren Fail 2006;28(4):331-5.

  • 21. Voegeli TA Kurtz A Grimm MO et al. Anemia under androgen deprivation: infl uence of fl utamide cyproteroneacetate and orchiectomy on the erythropoietin system. Horm Metab Res 2005;37(2):89-93.

  • 22. Malgor LA Valsecia M Vergés E De Markowsky EE. Blockade of the in vitro effects of testosterone and erythropoietin on Cfu-E and Bfu-E proliferation by pretreatment of the donor rats with cyproterone and fl utamide. Acta Physiol Pharmacol Ther Latinoam 1998;48(2):99-105.

  • 23. Claustres M Sultan C. Androgen and erythropoiesis: evidence for an androgen receptor in erythroblasts from human bone marrow cultures. Horm Res 1988;29:17-22.

  • 24. Naets JP Wittek M. The mechanism of action of androgens on erythropoiesis. Ann NY Acad Sci 1968;149:366-76.

  • 25. Ferrucci M Maggio S Bandinelli S et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006;166:1380-8.

  • 26. Rhoden EL Morgentaler A. Risks of testosteronereplacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92.

Journal information
Impact Factor

CiteScore 2018: 0.587

SCImago Journal Rank (SJR) 2018: 0.311

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 386 222 4
PDF Downloads 121 64 4